To this end we assessed 5 breast tumor samples with HER-2 immunohistochemistry (IHC) score 0 (group 1), 5 breast tumor samples with HER-2 IHC score 1+ / 2+ and fluorescence in situ hybridization (FISH) negative (group 2) and 5 breast tumor samples with HER-2 IHC score 3+ and FISH positive (group 3). This evidence concerns the gene ERBB2 and breast neoplasm.